BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ederth J, Jern C, Norder H, Magnius L, Alm E, Rognsvåg BK, Sundin CG, Brytting M, Esbjörnsson J, Mild M. Molecular characterization of HCV in a Swedish county over 8 years (2002-2009) reveals distinct transmission patterns. Infect Ecol Epidemiol 2016;6:30670. [PMID: 26854010 DOI: 10.3402/iee.v6.30670] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Ranjbar Kermani F, Amini-kafiabad S, Mousavi Hosseini K, Maghsudlu M, Sharifi Z, Mansournia MA. Distribution of Hepatitis C Virus Genotypes and Related Risk Factors Among Iranian Blood Donors: A Penalized Logistic Regression. Jundishapur J Microbiol 2018;11. [DOI: 10.5812/jjm.69136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Psaros Einberg A, Ekman AT, Söderhäll S, Millbourn C, Lindahl K, Harila-Saari A, Fischler B. Prevalence of chronic hepatitis C virus infection among childhood cancer survivors in Stockholm, Sweden. Acta Oncol 2019;58:997-1002. [PMID: 30761933 DOI: 10.1080/0284186X.2019.1574105] [Reference Citation Analysis]
3 Kjellin M, Wesslén T, Löfblad E, Lennerstrand J, Lannergård A. The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort. Ups J Med Sci 2018;123:50-6. [PMID: 29536805 DOI: 10.1080/03009734.2018.1441928] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]